Heron Therapeutics | HRTX - Cost Of Sales

Stock Price
1.20
Daily Change
-0.08 -5.91%
Monthly
-19.80%
Yearly
-28.01%
Q1 Forecast
2.71

Heron Therapeutics reported $9.46M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
ALKERMES USD 51.59M 2.13M Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amarin USD 16.89M 18.51M Mar/2025
ANI Pharmaceuticals USD 116.02M 18.12M Sep/2025
Anika Therapeutics USD 11.49M 35.48M Mar/2025
Eisai JPY 51.08B 5.56B Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Insmed USD 30.9M 1.56M Sep/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Merck USD 3.32B 531M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Omeros USD 33.16M 18.52M Jun/2024
Pacira USD 48.6M 6.59M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Surmodics USD 33.03M 24.58M Sep/2024
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Veracyte USD 41.21M 196K Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025